200 related articles for article (PubMed ID: 37464375)
1. Clinical development of mRNA therapies against solid tumors.
Wu D; Hu L; Wang X; Yu Y; Jia SP; Huang HY; Li ZW; Ma JF; Zhu HB; Tang Y; Li N
J Hematol Oncol; 2023 Jul; 16(1):75. PubMed ID: 37464375
[TBL] [Abstract][Full Text] [Related]
2. Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials.
Ingels J; De Cock L; Mayer RL; Devreker P; Weening K; Heyns K; Lootens N; De Smet S; Brusseel M; De Munter S; Pille M; Billiet L; Goetgeluk G; Bonte S; Jansen H; Lint SV; Leclercq G; Taghon T; Menten B; Vermaelen K; Impens F; Vandekerckhove B
Cytotherapy; 2022 Feb; 24(2):213-222. PubMed ID: 34696961
[TBL] [Abstract][Full Text] [Related]
3. Identification of alternative splicing-derived cancer neoantigens for mRNA vaccine development.
Cheng R; Xu Z; Luo M; Wang P; Cao H; Jin X; Zhou W; Xiao L; Jiang Q
Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35279714
[TBL] [Abstract][Full Text] [Related]
4. mRNA Cancer Vaccines.
Fiedler K; Lazzaro S; Lutz J; Rauch S; Heidenreich R
Recent Results Cancer Res; 2016; 209():61-85. PubMed ID: 28101688
[TBL] [Abstract][Full Text] [Related]
5. Neoantigens: promising targets for cancer therapy.
Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L
Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in mRNA cancer vaccines.
Yao R; Xie C; Xia X
Hum Vaccin Immunother; 2024 Dec; 20(1):2307187. PubMed ID: 38282471
[TBL] [Abstract][Full Text] [Related]
7. RNA-Based Vaccines in Cancer Immunotherapy.
McNamara MA; Nair SK; Holl EK
J Immunol Res; 2015; 2015():794528. PubMed ID: 26665011
[TBL] [Abstract][Full Text] [Related]
8. Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.
Shemesh CS; Hsu JC; Hosseini I; Shen BQ; Rotte A; Twomey P; Girish S; Wu B
Mol Ther; 2021 Feb; 29(2):555-570. PubMed ID: 33038322
[TBL] [Abstract][Full Text] [Related]
9. mRNA therapeutics in cancer immunotherapy.
Beck JD; Reidenbach D; Salomon N; Sahin U; Türeci Ö; Vormehr M; Kranz LM
Mol Cancer; 2021 Apr; 20(1):69. PubMed ID: 33858437
[TBL] [Abstract][Full Text] [Related]
10. mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer.
Malla R; Srilatha M; Farran B; Nagaraju GP
Mol Ther; 2024 Jan; 32(1):13-31. PubMed ID: 37919901
[TBL] [Abstract][Full Text] [Related]
11. Editorial: mRNA Vaccines and Immunotherapy in Oncology: A New Era for Personalized Medicine.
Parums DV
Med Sci Monit; 2021 May; 27():e933088. PubMed ID: 33994538
[TBL] [Abstract][Full Text] [Related]
12. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
13. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.
Fotin-Mleczek M; Zanzinger K; Heidenreich R; Lorenz C; Thess A; Duchardt KM; Kallen KJ
J Gene Med; 2012 Jun; 14(6):428-39. PubMed ID: 22262664
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
15. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
16. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
[TBL] [Abstract][Full Text] [Related]
17. Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines.
Lin F; Lin EZ; Anekoji M; Ichim TE; Hu J; Marincola FM; Jones LD; Kesari S; Ashili S
J Transl Med; 2023 Nov; 21(1):830. PubMed ID: 37978542
[TBL] [Abstract][Full Text] [Related]
18. mRNA Cancer Vaccines: Construction and Boosting Strategies.
Liu X; Huang P; Yang R; Deng H
ACS Nano; 2023 Oct; 17(20):19550-19580. PubMed ID: 37819640
[TBL] [Abstract][Full Text] [Related]
19. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
20. Tumor neoantigens: Novel strategies for application of cancer immunotherapy.
Guan H; Wu Y; Li LU; Yang Y; Qiu S; Zhao Z; Chu X; He J; Chen Z; Zhang Y; Ding H; Pan J; Pan Y
Oncol Res; 2023; 31(4):437-448. PubMed ID: 37415744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]